-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

3480 FAS Ablation Confers Resistance to Allogeneic CAR-T Rejection By T Cells in Absence of NK Cell Sensitization

Program: Oral and Poster Abstracts
Session: 711. Cell Collection and Manufacturing of HSPCs, CAR-T Cells, and Other Cellular Therapy Products: Poster II
Hematology Disease Topics & Pathways:
Research, Translational Research, Chimeric Antigen Receptor (CAR)-T Cell Therapies, Immune mechanism, Treatment Considerations, Biological therapies, Biological Processes
Sunday, December 8, 2024, 6:00 PM-8:00 PM

Silvia Menegatti, PhD1*, Sheila Lopez-Cobo, PhD1*, Aurelien Sutra Del Galy1*, Jaime Fuentealba, PhD1*, Lisseth Silva1*, Laeticia Perrin1*, Sandrine Heurtebise-Chrétien1*, Valentine Pottez-Jouatte, PhD1,2*, Aurélie Darbois1*, Nina Burgdorf1*, Albane Simon3*, Marguerite Laprie-Santenac, PharmD3*, Michael Saitakis, PhD4*, Bruce Wick, PhD5,6,7*, Beau R Webber, PhD5,6,7*, Branden S Moriarity, PhD5,6,7*, Olivier Lantz, MD, PhD1*, Sebastian Amigorena, PhD1* and Laurie Menger, PhD3*

1Institut Curie, PSL University, INSERM U932, Immunity and Cancer, Paris, France
2CellAction (Cell therapy Acceleration and Innovation), Institut Curie, Suresnes, France
3Gustave Roussy, Paris-Saclay University, INSERM U1015, Villejuif, France
4Mnemo Therapeutics, Paris, France
5Department of Pediatrics, University of Minnesota, Minneapolis, MN
6Masonic Cancer Center, University of Minnesota, Minneapolis, MN
7Center for Genome Engineering, University of Minnesota, Minneapolis, MN

Allogeneic chimeric antigen receptor T cells (allo-CAR-T) derived from healthy donors hold potential to overcome limitations associated with autologous cancer therapies, providing immediate access to standardized, affordable batches of CAR-T with improved efficacy. Concomitant to immune reconstitution, however, allogeneic CAR-T are rejected by the host’s immune system, resulting in reduced therapeutic efficacy and early relapses. To systematically identify targets overcoming allo-CAR-T rejection, we developed in vivo genome-wide CRISPR KO screens based on allogeneic T cell positive selection (screening for KO genes that promote resistance in fully mismatched immunocompetent mice). We show that Fas or B2m deletion increases the survival of allogeneic T cells in vitro and in vivo. Consequently, FAS or B2M silencing in anti-CD19 allo-CAR-T enhances their anti-leukemic activity and promotes mice survival. Nevertheless, while B2M KO allo-CAR-T become highly sensitive to NK cell-mediated rejection, FAS KO CAR-T, like control CAR-T, express normal levels of HLA-I and remain resistant to NK cell killing. We validated the results in a clinically relevant context using base-editing for multiplexing gene-KO in human CAR-T cells. CD3-FAS KO outperforms CD3-B2M KO CAR-T in the control of leukemia growth under allogeneic pressure by both T and NK cells. We conclude that CD3-FAS double-KO allogeneic CAR-T are partially protected from both T and NK cell-mediated allo-rejection, an approach with the potential to improve the efficacy of allogeneic cellular therapies in patients with B-cells neoplasms and more generally in cancer patients.

Disclosures: Webber: Luminary Therapeutics: Current Employment, Current equity holder in private company, Membership on an entity's Board of Directors or advisory committees, Patents & Royalties. Moriarity: Luminary Therapeutics: Current Employment, Current equity holder in private company, Membership on an entity's Board of Directors or advisory committees, Patents & Royalties.

*signifies non-member of ASH